Month-to-month Dividend Inventory in Focus: ChemTrade Logistics Earnings Fund

Printed on October sixteenth, 2024 by Aristofanis Papadatos

Traders on the lookout for a dependable and regular earnings stream might profit from investing in firms that pay month-to-month dividends. This may be extremely helpful when it comes to enhancing predictability and minimizing the uncertainty of a inventory.

That mentioned, there are simply 77 firms that at present provide a month-to-month dividend cost, which may severely restrict the investor’s choices. You possibly can see all month-to-month dividend paying names right here.

You possibly can obtain our full Excel spreadsheet of all month-to-month dividend shares (together with metrics that matter, like dividend yield and payout ratio) by clicking on the hyperlink under:

One identify that we’ve got not but reviewed is Chemtrade Logistics Earnings Fund (CGIFF), a Canadian-based belief that operates within the chemical compounds trade. At present, the inventory is providing a dividend yield of 5.9%, which is sort of 5 instances increased than the 1.2% yield of the S&P 500 Index.

Coupled with the truth that the belief pays out distributions on a month-to-month foundation, it might be an acceptable candidate for income-oriented traders.

This text will consider the belief, its enterprise mannequin, and its distribution to find out if Chemtrade Logistics could possibly be candidate for buy.

Enterprise Overview

Chemtrade Logistics Earnings Fund is a diversified belief that gives industrial chemical compounds and companies vital to the gasoline, motor oil, wonderful paper, metals, and water remedy industries and to different main industrial and client markets. The belief operates by way of two key segments: Sulphur & Water Chemical substances (SWC) and Electrochemicals (EC).

The SWC phase focuses on a variety of merchandise, together with Sulphur-based, water remedy, and specialty chemical compounds. As a number one provider of inorganic coagulants for water remedy in North America, Chemtrade’s SWC phase generated roughly 60% of the belief’s whole revenues final 12 months.

Then again, the EC phase primarily produces and markets Sodium Chlorate and Chlor-Alkali merchandise. Chemtrade is a major provider of Sodium Chlorate in Canada and Brazil, which is extensively utilized as a bleaching agent within the pulp and paper trade.

Moreover, its Chlor-Alkali merchandise are vital in supporting numerous processes in industries like metal, oil & gasoline, water remedy, and pulp & paper. Final 12 months, the EC phase generated the remaining 40% of the belief’s whole revenues.

Supply: Investor Presentation

In fiscal 2023, Chemtrade benefited from elevated demand for its chemical compounds and rising commodity costs, resulting in revenues reaching an all-time excessive degree of C$1.85 billion. This represents 2% progress in comparison with 2022 and 33% progress in comparison with 2021.

On account of such a major enhance in revenues, Chemtrade was in a position to leverage the numerous enhance in pricing and manufacturing volumes to extend its margins, leading to much more important progress in its profitability metrics. Its Adjusted EBITDA hit a brand new document of C$503 million, a rise of 17% year-over-year, whereas the belief’s distributable money after upkeep CAPEX landed at C$283 million, up 32% year-over-year.

For fiscal 2024, Chemtrade’s administration stays optimistic, seeing continued energy throughout each of its enterprise segments. Whereas the corporate might not match the document efficiency it achieved final 12 months, it’s poised to take care of above common outcomes this 12 months. The belief just lately raised its fiscal 2024 adjusted EBITDA steering from $395-$435 million to $430-$460 million.

The midpoint of this vary would characterize the second-highest degree the belief has ever generated, trailing solely its document 2023 outcomes. The truth is, following very sturdy efficiency throughout the first half of 2024, the belief might elevate its steering for the complete 12 months once more.

Development Prospects

Chemtrade has achieved important progress in its historical past, with its revenues and EBITDA rising at a compound annual progress price (CAGR) of three% and 11% during the last decade, respectively. This progress was achieved by way of a mix of accretive acquisitions, strategic divestments, and natural progress.

For instance, in 2017, the corporate acquired Canexus Company, which is understood for producing sodium chlorate and chlor-alkali merchandise at a low value. On the identical time, Chemtrade divested Aglobis, a smaller sulfur and sulphuric acid advertising and marketing enterprise.

Concerning natural progress, the corporate expects its present enterprise to profit from the ever-increasing demand for semiconductors. The CHIPS Act is anticipated to maintain driving progress within the semiconductor progress trade, with a number of new semiconductor fabrication crops underneath building within the U.S. As Chemtrade is the most important provider of UPA (Ultrapure Acid) in North America, it’s anticipated to proceed experiencing elevated demand.

Moreover, stricter rules and inhabitants progress are anticipated to maintain the rising demand for coagulants, which also needs to profit Chemtrade as one of many largest suppliers of inorganic coagulants for water remedy in North America.

Dividend Evaluation

According to its purpose of offering sustainable earnings for unitholders, Chemtrade has paid a month-to-month distribution since its inception.

Following a sequence of distribution cuts between 2003 and 2006 after a shaky IPO, Chemtrade paid a month-to-month distribution of C$0.11 between January 2007 and January 2020 (145 consecutive months). The month-to-month distribution was then halved at C$0.05, the place it has remained since.

As famous earlier, Chemtrade’s income and EBITDA progress appear spectacular at first sight, which can elevate questions on why the corporate wanted to scale back its month-to-month distribution. Nevertheless, it must be famous that Chemtrade distributed most of its income and that its progress was primarily pushed by acquisitions financed by way of debt and fairness issuance.

Because of elevated curiosity bills and dilution from distributing to a bigger variety of models, Chemtrade discovered itself in a tough place, which necessitated a discount in its month-to-month distribution to ensure that the corporate to strengthen its steadiness sheet.

The belief has achieved exceptional progress in that regard, as its web debt/LTM (Final Twelve Months) Adjusted EBITDA has already declined from 6.1X in Q2-2021 to 2.0X in Q2-2024. The payout ratio additionally improved dramatically following the distribution reduce, standing at 35% of distributable money this 12 months.

Supply: Investor Presentation

Regardless of the practically 23-year excessive rates of interest prevailing proper now, Chemtrade at present has a stable curiosity protection ratio of 5.6. As well as, it has web debt of $909 million, which is 92% of the present market capitalization of the inventory and therefore it’s manageable.

Contemplating the numerous progress made when it comes to lowering debt, the belief might resume elevating its distributions within the years to return, as it may well simply afford to. Alternatively, administration may select to take care of the present price of month-to-month payouts and as an alternative allocate capital in the direction of progress alternatives and additional deleveraging.

The latter situation appears extra believable, particularly provided that rates of interest stay excessive and that the models of Chemtrade are already hooked up to an above common 5.9% dividend yield.

Last Ideas

Chemtrade has a commendable monitor document of paying month-to-month distributions, though the discount in 2020 revealed some imprudent capital allocation by the administration prior to now decade.

Nonetheless, we predict that Chemtrade nonetheless provides a compelling possibility for income-oriented traders searching for reliable and frequent payouts. With seen natural progress avenues to capitalize on, important progress made in deleveraging in latest quarters, a cushty payout ratio, and a beneficiant yield of 5.9%, the belief’s funding case appears notably interesting.

Don’t miss the sources under for extra month-to-month dividend inventory investing analysis.

And see the sources under for extra compelling funding concepts for dividend progress shares and/or high-yield funding securities.